Analysts predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will post $0.70 earnings per share (EPS) for the current quarter, Zacks reports. Eight analysts have made estimates for Neurocrine Biosciences’ earnings. The lowest EPS estimate is $0.51 and the highest is $0.92. Neurocrine Biosciences reported earnings per share of $0.19 during the same quarter last year, which suggests a positive year-over-year growth rate of 268.4%. The company is expected to issue its next quarterly earnings results on Tuesday, February 4th.
According to Zacks, analysts expect that Neurocrine Biosciences will report full-year earnings of $0.70 per share for the current year, with EPS estimates ranging from $0.50 to $0.95. For the next financial year, analysts forecast that the business will post earnings of $3.35 per share, with EPS estimates ranging from $2.23 to $4.55. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.56 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.07). The firm had revenue of $222.09 million during the quarter, compared to analyst estimates of $211.31 million. Neurocrine Biosciences had a net margin of 3.12% and a return on equity of 5.67%. The company’s quarterly revenue was up 46.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.52 EPS.
Shares of Neurocrine Biosciences stock traded up $0.67 during trading on Monday, hitting $113.75. The stock had a trading volume of 698,100 shares, compared to its average volume of 807,274. The company has a debt-to-equity ratio of 0.83, a current ratio of 7.08 and a quick ratio of 6.99. The firm has a market cap of $10.41 billion, a P/E ratio of 517.05, a PEG ratio of 5.72 and a beta of 1.20. The business has a fifty day moving average of $99.77 and a two-hundred day moving average of $91.57. Neurocrine Biosciences has a fifty-two week low of $64.72 and a fifty-two week high of $116.06.
In related news, insider Darin Lippoldt sold 1,664 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $100.09, for a total transaction of $166,549.76. Following the transaction, the insider now directly owns 21,625 shares of the company’s stock, valued at $2,164,446.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dimitri E. Grigoriadis sold 5,000 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $115.98, for a total value of $579,900.00. Following the transaction, the insider now directly owns 113,408 shares in the company, valued at $13,153,059.84. The disclosure for this sale can be found here. Insiders have sold 57,795 shares of company stock worth $5,911,988 over the last three months. 4.30% of the stock is owned by insiders.
A number of hedge funds have recently modified their holdings of the business. Comerica Bank increased its position in Neurocrine Biosciences by 3.3% in the 3rd quarter. Comerica Bank now owns 3,933 shares of the company’s stock worth $386,000 after purchasing an additional 125 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Neurocrine Biosciences by 2.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 6,265 shares of the company’s stock worth $565,000 after acquiring an additional 135 shares in the last quarter. M&T Bank Corp boosted its stake in shares of Neurocrine Biosciences by 4.7% during the 2nd quarter. M&T Bank Corp now owns 3,377 shares of the company’s stock worth $286,000 after acquiring an additional 153 shares in the last quarter. JGP Global Gestao de Recursos Ltda. boosted its stake in shares of Neurocrine Biosciences by 5.6% during the 3rd quarter. JGP Global Gestao de Recursos Ltda. now owns 3,097 shares of the company’s stock worth $279,000 after acquiring an additional 163 shares in the last quarter. Finally, Virginia Retirement Systems ET AL boosted its stake in shares of Neurocrine Biosciences by 1.2% during the 3rd quarter. Virginia Retirement Systems ET AL now owns 17,000 shares of the company’s stock worth $1,532,000 after acquiring an additional 200 shares in the last quarter. 95.02% of the stock is currently owned by institutional investors.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Further Reading: The risks of owning bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.